Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Adeno-associated virus (AAV) vector gene therapy is a promising treatment for a variety of genetic diseases, including hemophilia. Systemic administration of AAV vectors is associated with a cytotoxic immune response triggered against AAV capsid proteins, which if untreated can result in loss of tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Samelson-Jones, Benjamin J., Finn, Jonathan D., Favaro, Patricia, Wright, J. Fraser, Arruda, Valder R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256432/
https://www.ncbi.nlm.nih.gov/pubmed/32490034
http://dx.doi.org/10.1016/j.omtm.2020.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256432/
https://www.ncbi.nlm.nih.gov/pubmed/32490034
http://dx.doi.org/10.1016/j.omtm.2020.05.001

Ejemplares similares